Protective Role of Oxcarbazepine in Multiple Sclerosis

OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial

CompletedPhase 2MS (type not specified)NCT021046612013-002419-87

What it found

No results found

We found no results in the registry or in papers.

This trial finished 8 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Oxcarbazepine

    Sodium channel alpha subunit blocker

Compared with

  • Oxcarbazepine

    Sodium channel alpha subunit blocker

Placebo

  • Placebo

What it measured

Main measures

  • Relative reduction of CSF neurofilament light chain levels

    From baseline to week 48

    Blood or spinal fluid markers

  • The primary objective is to assess whether OxCbz has a neuroprotective effect in participants with early SP or stable RRMS with history of progression, as measured by the stabilization or decrease of CSF NFL levels.

    Blood or spinal fluid markers

Other measures (6)

  • Safety of Oxcarbazepine in multiple sclerosis patients

    Ongoing throughout the trial

    Safety

  • Relative reduction of CSF neurofilament levels

    baseline, 24 weeks and 48 weeks

    Blood or spinal fluid markers

  • Change in clinical outcome measured by neurological examination.

    Baseline, week 24 and week 48

    Disability progression

  • Change in clinical outcome measured by cognitive assessment

    Baseline, week 12, 24, 36 and 48

    Thinking and memory

  • Change in patient reported outcomes measured by questionnaires

    Baseline, weeks 12, 24, 36 and 48

    FatigueWalking and mobilityPainQuality of life (reported by participants)

  • Change over 48 weeks of the study using clinical outcome measures: EDSS 30, and the Questionnaires (Including SF36, MSWS, MSIS-29 v2, Patient Pain Assessment, Patient Fatigue Assessment) and neurocognitive tests such as single digit modalities test (SDMT.

    Disability progressionThinking and memoryFatigueWalking and mobilityPainQuality of life (reported by participants)

Who could take part

MS (type not specified) · 18 to 60 · EDSS 3.5 to 6.0

Show the full criteria

Inclusion criteria

* A diagnosis of definite multiple sclerosis * Treatment with DMDs for at least 6 months prior to baseline visit* * CSF NFL level ≥ 0.380ng/mL * EDSS score between 3.5 and 6.0 * No history of relapses in the 6 months prior to the baseline visit * A history of slow progression of disability, objective or subjective, over a period of at least 6 months prior to baseline * Age 18-60 years * [Temporary interruption is permitted at the discretion of the investigator for a period of up to 8 weeks to prevent inflammatory MS reactivation. The cases where this could happen include for example switching DMDs that require a washout period as per clinical practice. When there are safety concerns, as in Lymphopenia or other side effects induced by the DMD, the interruption period can exceed 8 weeks as per clinical need. If reactivation of MS occurs with a relapse the investigator will assess if this meets withdrawal criteria 6.]

Exclusion criteria

* Pregnant or breastfeeding or unwilling to use adequate contraception.* * Participants with a diagnosis of primary progressive PP MS or primary relapsing PR MS. * A clinical relapse or pulsed intravenous or oral steroids in the 6 months preceding the baseline assessment. * Participants presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count \<500, neutrophil count \<1.5 or platelet count \<100, or thrombocytopenia \<1.5 LLN), or any medical condition which, in the opinion of the investigator, would pose additional risk to the participant. * Infection with hepatitis B or hepatitis C or human immunodeficiency virus. * Exposure to any other investigational drug within 30 days of enrolment in the study. * Judged clinically to have a suicidal risk in the opinion of the investigator based upon a clinical interview and the Columbia Suicide-Severity Rating Scale (CSSRS). * Prior history of malignancy unless an exception is granted by the Investigator. * History of uncontrolled drug or alcohol abuse within 6 months prior to screening. * Past untoward reactions to OxCbz or Cbz * Participants receiving OxCbz or Cbz in the previous 12 weeks from baseline * [Adequate methods of contraception are non hormonal methods such as barrier methods, intrauterine devices, surgical sterilisation (undergone by the participant or their partner). Female participants using hormonal only forms of contraception will be required to use an additional barrier method. True abstinence can be considered an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. Non sexually active participants or those in same sex relationships will not be required to commence contraception.]

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

People with multiple sclerosis (MS) have nerve loss even without acute inflammatory relapses, as obvious in the progressive phase of disease. Drugs that may prevent nerve loss work better in earlier stages when it is difficult to measure progressive disability. But it is now possible to measure the nerve loss as neurofilament light (NFL) in the cerebrospinal fluid (CSF). This is a trial of a neuroprotective drug, oxcarbazepine, which showed benefit in an animal model of multiple sclerosis. The investigators will use an innovative outcome, a reduction in the content of NFL in the CSF, as well as the usual clinical disability and imaging methods, to measure the success of the oxcarbazepine as a neuroprotective agent in MS. The use of NFL, a surrogate marker of neurodegeneration, allows a blinded and accurate outcome.

Papers

Loading reviews and guidelines…

Related trials

History

    1. Started

      Oct 2014

    2. Main results due

      Jan 2018

    3. Finished

      Jan 2018

    Assembled by software from public sources.